BCAL DiagnosticsASX:BDX -3.70% Market Cap is A$28.76 Mil as of Jun. 28, 2026. The stock has 3 warning signs investors should review. Among 219 Medical Diagnostics & Research companies, BCAL Diagnostics ranks worse than 69.41% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BCAL Diagnostics's share price for the quarter that ended in Dec. 2025 was A$0.105. BCAL Diagnostics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 368.07 Mil. Therefore, BCAL Diagnostics's market cap for the quarter that ended in Dec. 2025 was A$38.65 Mil.
BCAL Diagnostics's quarterly market cap
declined
from Dec. 2024 (A$35.50 Mil) to Jun. 2025 (A$23.06 Mil) but then
increased
from Jun. 2025 (A$23.06 Mil) to Dec. 2025 (A$38.65 Mil).
BCAL Diagnostics's annual market cap
increased
from Jun. 2023 (A$14.86 Mil) to Jun. 2024 (A$39.29 Mil) but then
declined
from Jun. 2024 (A$39.29 Mil) to Jun. 2025 (A$23.06 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BCAL Diagnostics's Enterprise Value for Today is A$28.87 Mil.
BCAL Diagnostics (ASX:BDX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BCAL Diagnostics Market Cap Related Terms
BCAL Diagnostics Market Cap Historical Data
* Premium members only.
The historical data trend for BCAL Diagnostics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BCAL Diagnostics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BCAL Diagnostics Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Market Cap distribution charts can be found below:
* The bar in red indicates where BCAL Diagnostics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BCAL Diagnostics's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCAL Diagnostics (ASX:BDX) has a Market Cap of A$28.76 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BCAL Diagnostics and its competitors. According to the industry distribution chart, BCAL Diagnostics ranks #152 out of 219 companies in the Medical Diagnostics & Research industry, placing it in the top 69.4%.
Is BCAL Diagnostics' Market Cap too high?
BCAL Diagnostics' current Market Cap is A$28.76 Mil. Based on the distribution chart, BCAL Diagnostics ranks #152 out of 219 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does BCAL Diagnostics' Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BCAL Diagnostics ranks #152 out of 219 companies for Market Cap. This places BCAL Diagnostics in the lower half of its industry. The industry median Market Cap is 55.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 55.76, based on 219 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BCAL Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 55.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BCAL Diagnostics's current Market Cap is A$28.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Market Cap of A$28.76 Mil. The current Market Cap is A$28.76 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Market Cap is A$28.76 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BDX has been successfully added to your 